Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397:1301–15.

Article  CAS  PubMed  Google Scholar 

Yu J, Zhao Q, Wang X, Zhou H, Hu J, Gu L, Hu Y, Zeng F, Zhao F, Yue C, et al. Pathogenesis, multi-omics research, and clinical treatment of psoriasis. J Autoimmun. 2022;133:102916.

Article  CAS  PubMed  Google Scholar 

Eder L, Chandran V, Pellett F, Shanmugarajah S, Rosen CF, Bull SB, Gladman DD. Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. Ann Rheum Dis. 2012;71:1361–5.

Article  PubMed  Google Scholar 

Luis Lopez-Estebaranz J, Luis Sanchez-Carazo J, Sulleiro S. Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: results from the ARIZONA study. J Dermatol. 2016;43:395–401.

Article  Google Scholar 

Ya J, Hu JZ, Nowacki AS, Khanna U, Mazloom S, Kabbur G, Husni ME, Fernandez AP. Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-α inhibitor-induced psoriasis: a case-control study. J Am Acad Dermatol. 2020;83:1599–605.

Article  CAS  PubMed  Google Scholar 

Frisell T, Saevarsdottir S, Askling J. Does a family history of RA influence the clinical presentation and treatment response in RA? Ann Rheum Dis. 2016;75:1120–5.

Article  PubMed  Google Scholar 

Morin M, Hellgren K, Lindstrom U, Frisell T. Is family history a predictor of response to tumour necrosis factor inhibitors in spondyloarthritis? A Swedish nationwide cohort study. Scand J Rheumatol. 2022;51:10–20.

Article  CAS  PubMed  Google Scholar 

Murata K, Hashimoto M, Yamamoto W, Son Y, Amuro H, Nagai K, Takeuchi T, Katayama M, Maeda Y, Ebina K, et al. The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study. Rheumatol Int. 2020;40:217–25.

Article  PubMed  Google Scholar 

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis a review. JAMA. 2020;323:1945–60.

Article  CAS  PubMed  Google Scholar 

Tsai Y-C, Tsai T-F. Switching biologics in psoriasis-practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13:493–503.

Article  CAS  PubMed  Google Scholar 

Huang D, Zhong X, Jiang Y, Kong L, Ma R, Lu J, Li Y, Shi Y. Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China. Br J Dermatol. 2024;191:616–23.

Article  PubMed  Google Scholar 

Yu N, Peng C, Zhou J, Gu J, Xu J, Li X, Bi X, Deng H, Li X, Ding Y, Shi Y. Measurement properties of the patient global assessment numerical rating scale in moderate-to-severe psoriasis. Br J Dermatol. 2023;189:437–46.

Article  PubMed  Google Scholar 

Ohata C, Anezaki H, Kaneko S, Okazaki F, Ito K, Matsuzaka Y, Kikuchi S, Koike Y, Murota H, Miyagi T, et al. Clinical characteristics of patients with psoriasis with family history: a multicenter observational study. J Dermatol. 2023;50:746–52.

Article  CAS  PubMed  Google Scholar 

Ferrándiz C, Pujol RM, García-Patos V, Bordas X, Smandía JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46:867–73.

Article  PubMed  Google Scholar 

Remrod C, Sjostrom K, Svensson A. Psychological differences between early- and late-onset psoriasis: a study of personality traits, anxiety and depression in psoriasis. Br J Dermatol. 2013;169:344–50.

Article  CAS  PubMed  Google Scholar 

Manzo Margiotta F, Michelucci A, Panduri S, Tonini A, Davini G, Romanelli M, Morganti R, Dini V. Family history of psoriasis: a novel protective factor for therapy switch in patients treated with secukinumab or ixekizumab. J Euro Acad Dermatol Venereol. 2022;36:E454–6.

Article  CAS  Google Scholar 

Torres T, Puig L, Vender R, Yeung J, Carrascosa J-M, Piaserico S, Gisondi P, Lynde C, Ferreira P, Bastos PM, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23:891–904.

Article  PubMed  Google Scholar 

Chiu H-Y, Hui RC-Y, Tsai T-F, Chen Y-C, Liao N-FC, Chen P-H, Lai P-J, Wang T-S, Huang Y-H. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8-year multicenter study. J Am Acad Dermatol. 2023;88:71–8.

Article  CAS  PubMed  Google Scholar 

Gudjonsson JE, Karason A, Antonsdottir A, Runarsdottir EH, Hauksson VB, Upmanyu R, Gulcher J, Stefansson K, Valdimarsson H. Patients with psoriasis who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003;148:233–5.

Article  CAS  PubMed  Google Scholar 

Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143:2120–30.

Article  CAS  PubMed  Google Scholar 

Siewertsen M, Al-Sofi R, Dridi H, Ajenthen GDD, Zachariae C, Skov L, Loft N. Association between HLA-Cw6 and response to treatment with biologics in patients with psoriasis: a systematic review and meta-analysis. J Euro Acad Dermatol Venereol. 2023;37:E611–4.

Article  CAS  Google Scholar 

van Vugt LJ, van den Reek JMPA, Hannink G, Coenen MJH, de Jong EMGJ. Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:708–15.

Article  PubMed  PubMed Central  Google Scholar 

Henseler T, Christophers E. Psoriasis of early and late onset—characterization of 2 types of psoriasis-vulgaris. J Am Acad Dermatol. 1985;13:450–6.

Article  CAS  PubMed  Google Scholar